Fig. 7: NAT10 promotes GBM malignant growth in vivo and correlates with clinicopathological features of glioma patients. | Cell Death & Disease

Fig. 7: NAT10 promotes GBM malignant growth in vivo and correlates with clinicopathological features of glioma patients.

From: NAT10-mediated N4-acetylcytidine (ac4C) modification of PIK3R2 mRNA promotes malignant progression of glioblastoma

Fig. 7

A, B LN229 and U87 cells with shNC and shNAT10 were orthotopically transplanted into the right striatum of mice (n = 5 per group). Tumor growth was evaluated by measuring fluorescence intensity using an in vivo imaging system. Statistical analysis was performed using Student’s t test. C, D Immunohistochemical staining of NAT10 and PIK3R2 in orthotopic tumor tissues. E Representative images showing NAT10 and PIK3R2 expression in low-grade and high-grade tumor samples. F Semi-quantitative scoring of NAT10 and PIK3R2 staining (0–12 points) with chi-square test for correlation. G Pearson correlation coefficient analysis of NAT10 and PIK3R2 expression in 30 glioma samples based on immunohistochemical scores. H Mechanism diagram summarizing the findings: NAT10 directly regulates PIK3R2 via ac4C modification, leading to PMT and promoting GBM malignant development. **p < 0.01, *p < 0.05.

Back to article page